RESUMO
OBJECTIVES: A multicenter, noninterventional, observational study was conducted in the Latin American countries including Argentina, Brazil, Colombia, Mexico, and Venezuela to assess the prevalence of liver and cardiac iron overload using magnetic resonance imaging (MRI) in patients with chronic anemias except thalassemia. METHODS: Patients aged >10 years with transfusion-dependent anemias, except thalassemia, either with <20 units of red blood cell (RBC) transfusions with serum ferritin (SF) levels >2000â ng/mL or with ≥20 units of RBC transfusions regardless of SF level in their lifetime, were enrolled. Iron overload was assessed using MRI. RESULTS: Among 175 patients included, the majority had sickle cell disease (SCD; 52%), followed by aplastic anemia (AA; 17.7%), myelodysplastic syndrome (MDS; 8.6%), Diamond-Blackfan anemia (DBA; 4%), pure red cell aplasia (1.1%), and others (16.6%). Liver iron overload was observed in 76.4% of patients, while cardiac iron overload was seen in 19.2% when assessed by MRI. The prevalence of iron overload was 80.2% in patients with SCD, 73.3% in MDS, 77.4% in AA, 100% in pure red cell aplasia, 71.4% in DBA, and 68.9% in other transfusion-related disorders. A moderate correlation between liver iron concentration (LIC) and SF was observed in patients with SCD and MDS (r = 0.47 and r = 0.61, respectively). All adverse events reported were consistent with the published data for deferasirox or underlying disease. CONCLUSION: A high prevalence of iron overload in this patient population in Latin American countries indicates that a better diagnosis and management of iron overload is required in these countries.
Assuntos
Anemia/metabolismo , Anemia/terapia , Transfusão de Eritrócitos , Sobrecarga de Ferro/metabolismo , Fígado/metabolismo , Miocárdio/metabolismo , Adolescente , Adulto , Anemia/patologia , Doença Crônica , Feminino , Ferritinas/metabolismo , Humanos , Sobrecarga de Ferro/epidemiologia , Sobrecarga de Ferro/etiologia , Sobrecarga de Ferro/patologia , América Latina/epidemiologia , Fígado/patologia , Masculino , Pessoa de Meia-Idade , Miocárdio/patologia , PrevalênciaRESUMO
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematologic disorders characterized by cytopenia(s) and predisposition to leukemic progression. An immune dysregulation and an aberrant bone marrow microenvironment seem to be key elements in the physiopathological process of MDS. In order to evaluate a possible association between susceptibility and clinic-pathologic features, we genotyped 153 MDS patients for functional cytokine polymorphisms: TNF (-308 G/A), IFNG (+874 A/T and +875 CAn), IL6 (-174 G/C), and TGFB1 (+869 C/T and +915 G/C). The frequency of TNF and IL6 polymorphisms was different between patients and healthy controls (n = 131), suggesting a relatedness to MDS susceptibility in our population. Furthermore, the presence of each or both high-producing genotypes [TNF: p = 0.048, odds ratio (OR): 3.979; IL6: p = 0.001, OR: 6.835; both: p = 0.010, OR: 6.068] and thrombocytopenia at platelet counts of <50,000/µL (p = 0.004, OR: 4.857) were independently associated with an increased risk of manifesting a hemoglobin level of <8 g/dL at diagnosis. In particular, a severe bicytopenia was more frequently observed in patients with the TNF (high)_IL6 (high) combined genotype (p = 0.004, OR: 8.357), who consistently became transfusion dependent earlier (2.9 vs. 34.6 months; p = 0.001); and this likelihood was more evident in patients with lower bone marrow blast counts. The contribution of the remaining functional polymorphisms to the disease phenotype was less relevant. Our results demonstrate that TNF and IL6 gene polymorphisms, as underlying host features, are likely to play a key role in influencing the severity of the cytopenias in MDS and they may be instrumental for tailoring cytokine-target therapies.
Assuntos
Predisposição Genética para Doença/genética , Interleucina-6/genética , Síndromes Mielodisplásicas/genética , Pancitopenia/complicações , Polimorfismo de Nucleotídeo Único , Fator de Necrose Tumoral alfa/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Argentina , Feminino , Frequência do Gene , Genótipo , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Síndromes Mielodisplásicas/complicações , Pancitopenia/patologia , Estudos Prospectivos , Estudos Retrospectivos , Índice de Gravidade de Doença , Trombocitopenia/complicações , Adulto JovemRESUMO
There are previously reported data describing differences between Asian and European patients with Myelodysplastic Syndromes (MDS), few direct comparisons based on cancer registration characteristics or using cohorts to validate scoring systems. This is the first study from South-America, which attempts to describe demographic, clinical features, and outcome of MDS patients. We retrospectively analyzed 1,080 patients with de novo MDS from Argentina (635), Brazil (345), and Chile (100). Chilean patients were younger (P = 0.001) with female preponderance (P = 0.071). Brazilian series showed a higher predominance of RARS subtype regarding FAB and WHO classifications (P < 0.001). Hemoglobin levels were significantly lower in Brazilian and Chilean series (P < 0.001), and Chilean series also showed a lower platelet count (P = 0.028), with no differences concerning the neutrophil count, % BM blast, and the distribution of cytogenetic risk groups (P > 0.05). Chilean series depicted a lower overall survival (OS; 35 months vs. 56 months-Argentine; 55 months-Brazil, P = 0.030), which was consistent with a higher predominance of the high-risk group according both to the IPSS and IPSS-R (P = 0.046 and P < 0.001). The IPSS-R system and its variables showed a good reproducibility to predict clinical outcome for the whole South-American population. Epidemiological and clinical characteristics, distribution among prognostic subgroups, the OS, and the access to disease modifying therapies were more similar between Argentinean and Brazilian compared with Chilean MDS series. This will need further analysis in a larger group of patients. Descriptive and comparative studies are necessary to establish epidemiological features useful for public health attitudes to generate suitable therapeutic schemes.
Assuntos
Síndromes Mielodisplásicas/mortalidade , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/terapia , Estudos Retrospectivos , América do Sul/epidemiologiaRESUMO
Eliglustat is an investigational, oral substrate reduction therapy for Gaucher disease type 1 (GD1). Nineteen treatment-naïve patients have now completed 4years of an open-label study (NCT00358150). Mean hemoglobin level and platelet count increased by 2.3±1.5g/dL (baseline: 11.3±1.5g/dL) and 95% (baseline: 68,700±21,200/mm(3)), respectively. Mean spleen and liver volumes (multiples of normal, MN) decreased by 63% (baseline: 17.3±9.5 MN) and 28% (baseline: 1.7±0.4 MN), respectively. Median chitotriosidase and CCL-18 each decreased by 82%; plasma glucosylceramide and GM3 normalized. Mean bone mineral density T-score for the lumbar spine increased by 0.8 (60%) (baseline: -1.6±1.1). Femur dark marrow, a reflection of Gaucher cell infiltration into bone marrow, was reduced or stable in 17/18 patients. There were no bone crises. Most adverse events were mild and unrelated to treatment. These results extend the safety and efficacy of eliglustat reported at 1 and 2 years to 4 years.
Assuntos
Drogas em Investigação/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Doença de Gaucher/tratamento farmacológico , Pirrolidinas/uso terapêutico , Adolescente , Adulto , Densidade Óssea , Medula Óssea/efeitos dos fármacos , Medula Óssea/patologia , Quimiocinas CC/sangue , Feminino , Seguimentos , Gangliosídeo G(M3)/sangue , Doença de Gaucher/sangue , Doença de Gaucher/patologia , Glucosilceramidas/sangue , Hemoglobinas/metabolismo , Hexosaminidases/sangue , Humanos , Vértebras Lombares/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Contagem de PlaquetasRESUMO
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematological diseases characterized by refractory cytopenia(s). MDS patients show increased levels of tumor necrosis factor alpha (TNFα) which is a multifunctional proinflammatory cytokine. The aim of this work is to examine the presence of -308A/G TNFα variants and to analyze whether it is associated with clinical parameters in a cohort of 101 Argentinean de novo MDS patients. The A/A+A/G genotype at TNFα -308 was overrepresented 2-fold in our population (p=0.0499, odds ratio-OR: 2.107) and these differences were more evident in RA-FAB subtype (p=0.0424, OR: 2.502). The presence of the high expressing -308A allele was associated with lower hemoglobin level (8.3 vs 9.9g/dL; p=0.0206), reduced platelet counts (89,000 vs 130,000/µL; p=0.0381) and younger age (59 vs 68years; p=0.0122) at diagnosis. Also, these patients showed 3.8-fold higher risk of transfusion requirement (76% vs 46%, p=0.0105) during the follow up. In conclusion, the presence of an inherited -308A TNFα, which increases its transcription level, was associated with the MDS phenotype in our cohort of Argentine MDS patients. Also, an overexpression of TNFα may promote an underlying proinflammatory state that cooperates with intrinsic defects within MDS progenitors to increase the severity of certain phenotypic features of the disease.
Assuntos
Anemia/complicações , Anemia/genética , Síndromes Mielodisplásicas/complicações , Síndromes Mielodisplásicas/genética , Trombocitopenia/complicações , Trombocitopenia/genética , Fator de Necrose Tumoral alfa/genética , Idoso , Alelos , Feminino , Estudos de Associação Genética , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Myelodysplastic syndromes (MDS) include a group of heterogeneous hematological disorders with a variable risk of leukemic evolution and short survival. Around 40-50% of patients show abnormal karyotypes that are mostly characterized by monosomies or deletions. Cytogenetic findings are an independent prognostic factor and the International prognostic scoring system (IPSS) differentiates three cytogenetic categories, despite the Intermediate one being heterogeneous. The aim of this study, including 421 Argentinean patients with primary MDS, is to characterize the cytogenetic profile, to test its prognostic value and to compare partial and monosomal karyotypes against other cytogenetic findings. An abnormal karyotype (median survival: 26 months) was observed in 176 patients. The presence of complex karyotypes, number of alterations, and the IPSS cytogenetic groups showed significant differences for predicting outcome. Behavior of patients with isolated deletions (median survival: 49 months) did not differ from those with normal karyotype (56 months, P = 0.654) or Good prognostic findings (43 months, P = 0.371). However, a worse prognosis was observed when another alteration was added (31 months, P = 0.043). Karyotypes with autosomal monosomies (median survival: 16 months) had a prognostic impact similar to other Poor cytogenetic findings (17 months, P = 0.626). In our population classified according to French-American-British (FAB) or World Health Organization (WHO), this new categorization of cytogenetic abnormalities, recognizing three different risk groups, showed an independent prognostic impact and a better discriminating power than the IPSS categories. It can be concluded that all isolate deletions (excluding 7q-) are good prognostic findings and all monosomies (excluding Y chromosome loss) are bad indicators.
Assuntos
Cromossomos Humanos/genética , Monossomia , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/mortalidade , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Argentina/epidemiologia , Deleção Cromossômica , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de SobrevidaRESUMO
The results of a meeting of physicians convening in Latin America to develop expert opinions on the diagnosis, monitoring and treatment of iron overload are as follows. An accurate diagnosis can be obtained by neonatal screening for haemoglobinopathies, especially sickle cell disease and the thalassaemias. Disease-specific registries are needed to demonstrate the extent of the problem to health authorities. Disparities in the quantity and quality of blood products must be addressed, and uniform transfusion guidelines are necessary. Serum ferritin level is a feasible marker for iron overload in the region, while magnetic resonance imaging assessment can improve the diagnosis and monitoring of cardiac and liver iron content. Medical specialists, including radiologists, pathologists and others, and health authorities, can help to implement these methods and provide adequate resources. The recently available oral deferasirox can be used to conveniently administer iron chelation to transfusional iron-overloaded patients.
Assuntos
Sobrecarga de Ferro/diagnóstico , Sobrecarga de Ferro/terapia , Humanos , Recém-Nascido , América LatinaRESUMO
BACKGROUND: Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia, requires regular subcutaneous or intravenous infusions. This can lead to reduced quality of life and poor adherence, resulting in increased morbidity and mortality in iron-overloaded patients with beta-thalassemia. Deferasirox is an orally administered iron chelator that has been approved for use in the United States, Switzerland, and other countries. OBJECTIVE: This analysis was conducted to compare patient-reported outcomes (PROs) during receipt of DFO infusions or once-daily oral therapy with deferasirox (ICL670). METHODS: PROs were prospectively evaluated as part of a randomized, Phase III study comparing the efficacy and safety profile of DFO 20 to 60 mg/kg per day with those of deferasirox 5 to 30 mg/kg per day in patients (age > or =2 years) with beta-thalassemia who were receiving regular transfusions and had a liver iron concentration of > or =2 mg/g dry weight. PRO questionnaires were completed by patients or a parent or legal guardian at baseline, week 4, week 24, and end of study (EOS). Patients assessed their level of satisfaction with study treatment (very satisfied, satisfied, neutral, dissatisfied, or very dissatisfied) and rated its convenience (very convenient, convenient, neutral, inconvenient, or very inconvenient). Time lost from normal activities due to ICT in the previous 4 weeks was recorded using a single global assessment. At week 4, patients who had previous experience with DFO were asked to indicate their preference for treatment (ICT received before the study, ICT received during the study, no preference, or no response) and the reason for that preference. At EOS, all patients were asked if they would be willing to continue using the ICT they had received during the study. All study analyses were performed in all patients who received at least 1 dose of study medication. RESULTS: Five hundred eighty-six patients (304 females, 282 males; age range, 2-53 years) received treatment with DFO (n = 290) or deferasirox (n = 296). Significantly more patients treated with deferasirox reported being very satisfied or satisfied with treatment compared with those treated with DFO (week 4: 92.0% vs 50.4%, respectively; week 24: 89.6% vs 44.0%; EOS: 85.1% vs 38.7%; all, P < 0.001). At the same time points, the majority of those treated with deferasirox reported that treatment was very convenient or convenient compared with those treated with DFO (95.5% vs 21.3%, 91.7% vs 17.4%, and 92.7% vs 11.3%, respectively; all, P < 0.001). Among patients who had previously taken DFO and were randomized to receive deferasirox during the study, 96.9% reported a preference for deferasirox over DFO. At EOS, the proportion of patients indicating a willingness to continue study therapy was significantly greater in those receiving deferasirox than in those receiving DFO (85.8% vs 13.8%; P < 0.001). CONCLUSIONS: In this study, patient-reported satisfaction and convenience were significantly higher for the once-daily, oral ICT deferasirox than for DFO infusions. Among patients who had received DFO before the study, the majority indicated a preference for deferasirox over DFO. Most patients receiving deferasirox indicated that they would be willing to continue taking it. These results suggest that deferasirox had a positive impact on patients' daily lives.
Assuntos
Antídotos/uso terapêutico , Benzoatos/uso terapêutico , Desferroxamina/uso terapêutico , Sobrecarga de Ferro/tratamento farmacológico , Triazóis/uso terapêutico , Talassemia beta/tratamento farmacológico , Adolescente , Adulto , Criança , Pré-Escolar , Deferasirox , Feminino , Humanos , Sobrecarga de Ferro/etiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Talassemia beta/complicaçõesRESUMO
Los síndromes mielodisplásicos (SMD) comprenden un grupo heterogéneo de desordenes hematólogicos con riesgo de evolución a leucemia mieloide aguda (LMA). El Grupo Franco-Americano-Británico (FAB) los clasifica en cinco entidades morfológicas y el Sistema Pronóstico Internacional (IPSS) propone cuatro grupos de riesgo basándose en variables clínicas y citogenéticas. El objetivo del trabajo fue evaluar la aplicación del IPSS en población Argentina, analizar el valor pronóstico de sus variables y determinar si dicho sistema permite identificar subgrupos pronósticos de riesgo dentro de los subtipos FAB. Se evaluaron 234 pacientes con SMD de novo (Media de seguimiento: 28 meses), con el fin de determinar sobrevida (SV) y sobrevida libre de LMA (SLL). Se analizaron la clasificación FAB y el IPSS, así como sus variables (número de citopenias, porcentaje de blastos, grupos de riesgo citogenético). Los resultados mostraron diferencias significativas para SV y SLL. La aplicación del IPSS permitió la diferenciación de los cuatro grupos de riesgo y ayudó a identificar subclases pronósticas dentro de los subtipos FAB: 5 , 15 y 19 por ciento de pacientes con peor pronóstico dentro de los subtipos Anemia Refractaria (AR), AR con sideroblastos en anillo (ARSA) y AR con exceso de blastos (AREB), respectivamente. El IPSS no fue informativo para el subtipo AREB en transformación, ni tampoco en pacientes con leucemia mielomonocítica crónica.
Assuntos
Humanos , Masculino , Adolescente , Adulto , Pessoa de Meia-Idade , Feminino , Leucemia Mieloide/epidemiologia , Leucemia Mieloide/etiologia , Pré-Leucemia/epidemiologia , Síndromes Mielodisplásicas/classificação , Síndromes Mielodisplásicas/epidemiologia , Síndromes Mielodisplásicas/genética , Argentina/epidemiologia , Contagem de Células Sanguíneas , Exame de Medula Óssea , Linhagem da Célula , Aberrações Cromossômicas , Tábuas de Vida , Progressão da Doença , Fatores de Risco , Índice de Gravidade de Doença , Análise de SobrevidaRESUMO
Los Síndromes Mielodisplásicos (SMD) comprenden un grupo heterogéneo de desórdenes hematológicos con riesgo de evolución leucémica. En este trabajo se evaluó el valor pronóstico del cariotipo al momento del diagnóstico, teniendo en cuenta el International Prognostic Scoring System (IPSS). Dicho puntaje propone 3 grupos pronósticos para la variable citogenética: Bueno (cariotipo normal, del(5q), del(20q) o -Y), Intermedio (+8 y misceláneas) y Malo (-7/del(7q) o alteraciones complejas). En este estudio se evaluaron 198 pacientes (95 AR, 13 AS, 43 AREB, 23 AREBt y 24 LMMC) distribuidos, de acuerdo al IPSS en: 60 Bajo riesgo, 76 Intermedio 1, 32 Intermedio 2 y 30 Alto riesgo (media de seguimiento: 28 meses). Los resultados citogenéticos de médula ósea se agruparon en: 126 Bueno, 41 Intermedio y 31 Malo, con una mediana de Sobrevida de 60, 34 y 28 meses (p=0.013) y una Evolución Leucémica (25porciento) de 46, 19 y 5 meses (p<0.001), respectivamente. El cruzamiento entre los grupos citogenéticos y el IPSS mostró que el 84 porciento de los pacientes pertenecientes al grupo citogenético Bueno correspondían al riesgo Bajo e Intermedio-l, el 61 porciento del grupo citogenético Intermedio presentaban riesgo Intermedio-l; mientras que, el 84 porciento perteneciente al grupo citogenético Malo pertenecían a los grupos de riesgo Intermedio-2 y Alto. Estos datos muestran una importante asociación (p<0.001) entre el estudio citogenético y los grupos de riesgo determinados por el IPSS. Lo cual indica la importancia del cariotipo, aparte del porcentaje de blastos y las citopenias, para individualizar grupos pronósticos en los SMD.
Assuntos
Análise Citogenética , Doenças HematológicasRESUMO
BACKGROUND AND OBJECTIVES: Myelodysplastic syndromes (MDS) comprise a group of heterogeneous hematologic disorders with risk of leukemic evolution (LE). The French-American-British (FAB) co-operative group classifies them into five morphologic entities and the International Prognostic Scoring System (IPSS) proposes four groups of risk on the basis of clinical and cytogenetic variables. The aim of this study was to evaluate the application of the IPSS in our Argentine population, to test the prognostic value of its variables and to determine whether this score helps to associate prognostic subgroups of risk into FAB subtypes. DESIGN AND METHODS: Two hundred and thirty-four patients with primary MDS and a median follow-up of 28 months were evaluated using univariate analyses to determine median survival (SV) and the time to LE. The variables analyzed were FAB classification, IPSS, percentage of myeloblasts, cytogenetic groups of risk and number of cytopenias. RESULTS: Univariate analyses showed that all variables analyzed were predictive for SV and for LE in our MDS population. Application of the IPSS allowed discrimination into the 4 groups of risk and helped to identify prognostic subclasses among the FAB classification, associating 5%, 15% and 19% of cases with worse prognosis within the FAB classification of refractory anemia (RA), RA with ringed sideroblasts and RA with excess of blasts (RAEB), respectively. The IPSS was not informative for RAEB in transformation cases and would not be applied to patients with chronic myelomonocytic leukemia. INTERPRETATION AND CONCLUSIONS: This score could be applied to our MDS population, showing no geographic differences. Stratification of FAB patients according to IPSS would be helpful to develop risk-adapted therapeutic strategies.
Assuntos
Leucemia Mieloide/epidemiologia , Síndromes Mielodisplásicas/epidemiologia , Pré-Leucemia/epidemiologia , Índice de Gravidade de Doença , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Aneuploidia , Argentina/epidemiologia , Contagem de Células Sanguíneas , Medula Óssea/patologia , Exame de Medula Óssea , Linhagem da Célula , Aberrações Cromossômicas , Progressão da Doença , Feminino , Humanos , Cariotipagem , Leucemia Mieloide/etiologia , Tábuas de Vida , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/classificação , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/patologia , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Análise de SobrevidaRESUMO
Se estudiaron 57 episodios febriles en 42 pacientes internados con el diagnóstico de leucemia aguda, y cifras iguales o menores de 1000 neutrófilos por milímetro cúbico. Las combinaciones antimicrobianas empíricas utilizadas más frecuentemente fueron Cefalotina + Amikacina y Cefuroxine + Mezlocilina; no pudimos establecer la superioridad terapéutica de ningún régimen sobre el otro. De los 57 episodios febriles, 37 cursaron desde el inicio con neutrófilos inferiores a 500/mm3. Los focos probables de infección fueron fundamentalmente el mucocutáneo y el pulmonar (49 y 31,5%, respectivamente). El foco abdominal se asoció a pronóstico severo. Hubo aislamientos microbiológicamente documentados en un 60%, con predominio de agentes Gram positivos con respecto a enterobacterias y Pseudomonas aeruginosa. La evolución de los procesos infecciosos mantuvo estrecha relación con la posibilidad de recuperación de la enfermedad de base